Top Markets
Coin of the day
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Peringkat dalam Saham #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Harga Saham
$0.41
Terakhir disinkronkan: 2025-01-23
Kapitalisasi Pasar
$1.08M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan CohBar, Inc. (CWBR)

Kategori

Rasio P/E untuk CohBar, Inc. (CWBR)
Rasio P/E per August 2026 TTM: -0.10
Menurut laporan keuangan dan harga saham terbaru dari CohBar, Inc., rasio P/E saat ini (TTM) adalah -0.10. Pada akhir 2021, perusahaan memiliki rasio P/E sebesar -1.51.
Riwayat rasio P/E untuk CohBar, Inc. dari 2011 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
2026 (TTM) -0.10 -75.78%
2022 -0.41 -72.77%
2021 -1.51 -66.15%
2020 -4.47 -10.93%
2019 -5.02 -38.56%
2018 -8.17 -56.87%
2017 -18.94 69.45%
2016 -11.18 21.87%
2015 -9.17 -32.62%
2014 -13.61 -34.01%
2013 -20.62 79.87%
2012 -11.46 0.00%
2011 0.00 0.00%
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
28.05 -28,345.92%
US
31.14 -31,463.75%
NL
- -
CH
- -
KR
19.30 -19,534.74%
BE
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.